Genentech recently announced positive results from a Phase III clinical trial in giant cell arteritis (GCA) There have been no new therapies for GCA in more than 50 years Breakthrough Therapy Designation was granted to Actemra for the treatment of GCA by the FDA in 2016 South San Francisco, CA — January 23, 2017 —...